ISR - IsoRay Is Branching Out

• IsoRay is a specialist of brachytherapy using proprietary radioactive seeds based on Cesium-131 to cheaply, safely and effectively treat certain cancers.
• Its main market is that for certain prostate cancer treatments and that has been affected by the pandemic, but there is a large and growing backlog.
• The company is venturing out, treating other cancers and embarking on combination therapies and embracing new imaging methods.
• Recent substantial share price gains and financing deals seem to have absorbed much of the near-term prospects for investors, even if the company now has cash for years to come.

For further details see: